United States Patent 6,361,758: A Detailed Analysis of Scope, Claims, and Patent Landscape
Introduction
United States Patent 6,361,758, titled "Cosolvent Formulations," was issued on March 26, 2002, to Abbott Laboratories. This patent is significant in the pharmaceutical industry, particularly for the formulation of lipophilic therapeutic agents. Here, we will delve into the scope, claims, and the broader patent landscape surrounding this invention.
Background and Invention Overview
The patent 6,361,758 pertains to pharmaceutical formulations designed to solubilize lipophilic (fat-soluble) therapeutic agents in largely aqueous vehicles. This is crucial for enhancing the bioavailability and stability of these agents, which are often poorly soluble in water[4].
Scope of the Patent
The scope of the patent encompasses several key aspects:
Pharmaceutical Formulations
The invention focuses on creating formulations that can effectively solubilize lipophilic agents. This is achieved through the use of cosolvents, which are solvents that, when combined with water, can dissolve substances that are otherwise insoluble in water alone[4].
Solubilization Process
The patent describes methods for preparing these formulations, including the selection of appropriate cosolvents and the process of mixing these components to achieve stable and effective formulations.
Therapeutic Agents
The patent is applicable to a wide range of lipophilic therapeutic agents, which are essential in various medical treatments. The solubilization of these agents enhances their efficacy and makes them more suitable for administration.
Claims of the Patent
The patent includes several claims that define the scope of the invention:
Independent Claims
These claims outline the core aspects of the invention, such as the composition of the formulation, the method of preparation, and the specific use of cosolvents to solubilize lipophilic agents.
Dependent Claims
These claims build upon the independent claims, providing additional details and specifications. For example, they may specify particular cosolvents, the ratio of components, and the conditions under which the formulations are prepared[4].
Patent Landscape
Related Patents
The patent 6,361,758 is part of a family of patents related to cosolvent formulations and pharmaceutical solubilization. Other patents, such as U.S. Patent 6,136,799, also issued to Abbott Laboratories, cover similar but distinct aspects of cosolvent formulations[2].
Global Patent Family
This patent is also part of an international patent family, with corresponding patents filed in other countries, such as Canada (Patent 2498331). These international filings indicate the global relevance and protection of the invention[4].
Litigation and Enforcement
The patent has been involved in litigation, as seen in cases where Abbott Laboratories and other stakeholders have defended their intellectual property rights against alleged infringers. For example, in the case against Sandoz Inc. and Sandoz Canada Inc., the plaintiffs alleged infringement of several patents, including the '758 Patent[2].
Economic and Research Implications
Patent Claims Research Dataset
The USPTO's Patent Claims Research Dataset provides insights into the claims and scope of patents like 6,361,758. This dataset, which includes detailed information on claims from U.S. patents granted between 1976 and 2014, can be used to analyze the breadth and depth of patent protection in the pharmaceutical sector[3].
Industry Impact
Patents like 6,361,758 play a crucial role in the pharmaceutical industry by protecting innovative formulations that enhance drug efficacy and patient outcomes. They also influence research and development by encouraging further innovation and investment in new formulations.
Expiration and Current Status
The patent 6,361,758 expired on April 8, 2018, which means that the protected formulations and methods are now in the public domain. This expiration can lead to increased competition and the development of generic versions of the formulations[2].
Conclusion
United States Patent 6,361,758 represents a significant contribution to the field of pharmaceutical formulations, particularly for lipophilic therapeutic agents. The patent's scope and claims provide a detailed framework for understanding the invention, and its place within the broader patent landscape highlights its importance and impact on the industry.
Key Takeaways
- Pharmaceutical Formulations: The patent focuses on solubilizing lipophilic therapeutic agents in aqueous vehicles.
- Cosolvent Use: The invention utilizes cosolvents to enhance solubility.
- Claims and Scope: The patent includes independent and dependent claims defining the composition, preparation, and use of the formulations.
- Patent Family: The patent is part of an international family with corresponding filings in other countries.
- Litigation: The patent has been involved in litigation to protect intellectual property rights.
- Economic Impact: The patent influences research, development, and competition in the pharmaceutical industry.
- Expiration: The patent expired on April 8, 2018, making the formulations public domain.
FAQs
What is the main focus of United States Patent 6,361,758?
The main focus is on pharmaceutical formulations designed to solubilize lipophilic therapeutic agents in largely aqueous vehicles.
Who is the assignee of the patent?
The patent is assigned to Abbott Laboratories.
What is the significance of cosolvents in this patent?
Cosolvents are used to enhance the solubility of lipophilic agents in water, making the formulations more effective.
Is the patent still in force?
No, the patent expired on April 8, 2018.
How does this patent impact the pharmaceutical industry?
It protects innovative formulations, encourages further research and development, and influences competition within the industry.
Are there corresponding international patents for this invention?
Yes, there are corresponding patents filed in other countries, such as Canada.
